

Table 1S. CVID⁺/CMV⁻ cohort: clinical characteristics.

PATIENT	AGE/ GENDER	GENETIC DIAGNOSIS	AGE OF CVID SYMPTON ONSET	AGE AT CVID DIAGNOSIS/	INFLAMMATORY DISEASE [#]	IATROGENIC IMMUNOSUPPRESSION	INFECTIONS
7	35M	No pathogenic variant identified	25	34	Nil	Nil	Recurrent sinopulmonary & soft tissue infections
8	62F	No pathogenic variant identified	31	45	Lymphadenopathy	Nil	Recurrent sinopulmonary infections, small intestinal bacterial overgrowth
9	33F	<i>NFKB1</i> : c.730+4A>G	16	29	Lymphocytic enteropathy, mild bronchiectasis	Nil	Recurrent sinopulmonary infections

[#] Inflammatory disease defined as the presence of autoimmune cytopenias, autoimmune haemolytic anaemia (AIHA), enteropathy, lymphadenopathy/splenomegaly, lymphoproliferative disease, interstitial lung disease or seronegative spondyloarthritis, WES: Whole Exome Sequencing.

Table 2S. CVID⁺/CMV⁻ cohort: immunological characteristics.

	Patient 7	Patient 8	Patient 9
Total lymphocyte count , cells x 10 ⁹ , [1.0-4.8]*	1.8	6.7	3.2
CD19+ , cells x 10 ⁹ , [0.07-0.55]	0.02	1.52	0.72
CD3+ , cells x 10 ⁹ , [0.60-2.50]	1.64	4.93	2.07
CD4+ , cells x 10 ⁹ , [0.45-1.70]	1.02	3.88	1.41
CD8+ , cells x 10 ⁹ , [0.20-1.15]	0.59	0.91	0.56
CD4:CD8 , [1.1-2.4]	1.74:1	4.27:1	2.49:1
CD56+ , cells x 10 ⁹ , [0.07-0.70]	0.16	0.19	0.32

*[reference range]; values outside reference range in **bold**.